glp-1 parkinson's disease lancet Neuroprotective effects of class drugs in GLP-1 receptor agonists in Parkinson's

Subcutaneous injections

A members-only digital community for a judgment-free space with peer groups for life on weight management medications

Given the relatively smaller reduction in body weight (9.4%) in the SELECT trial compared to previous RCTs: 14.9% in STEP1 (BMI 37.86.7 kg/m 2 ) [16] and 13.2% STEP6 (BMI 31.9 kg/m 2 ) [49], pleiotropic effects of semaglutide may contribute to the overall CV risk reduction [25,37]

While prior research has focused on policy-level data, Ro's and Amgen's will importantly evaluate real-world GLP-1 coverage among a treatment-seeking population

Functional medicine experts emphasize this difference

Endoscopic retrograde cholangiopancreatography (ERCP)-related adverse events: post-ERCP pancreatitis